Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment

被引:0
|
作者
Kayla V. Myers
Sarah R. Amend
Kenneth J. Pienta
机构
[1] The Johns Hopkins School of Medicine,Department of Pharmacology and Molecular Sciences
[2] The Johns Hopkins School of Medicine,The James Buchanan Brady Urological Institute, Department of Urology
[3] The Johns Hopkins School of Medicine,Department of Oncology
[4] Johns Hopkins University,Department of Chemical and Biomolecular Engineering
来源
Molecular Cancer | / 18卷
关键词
Macrophage; TAM receptors; Tyro3; Axl; MerTK; Efferocytosis; M2 macrophage polarization;
D O I
暂无
中图分类号
学科分类号
摘要
Tumor-associated macrophages are an abundant cell type in the tumor microenvironment. These macrophages serve as a promising target for treatment of cancer due to their roles in promoting cancer progression and simultaneous immunosuppression. The TAM receptors (Tyro3, Axl and MerTK) are promising therapeutic targets on tumor-associated macrophages. The TAM receptors are a family of receptor tyrosine kinases with shared ligands Gas6 and Protein S that skew macrophage polarization towards a pro-tumor M2-like phenotype. In macrophages, the TAM receptors also promote apoptotic cell clearance, a tumor-promoting process called efferocytosis. The TAM receptors bind the “eat-me” signal phosphatidylserine on apoptotic cell membranes using Gas6 and Protein S as bridging ligands. Post-efferocytosis, macrophages are further polarized to a pro-tumor M2-like phenotype and secrete increased levels of immunosuppressive cytokines. Since M2 polarization and efferocytosis are tumor-promoting processes, the TAM receptors on macrophages serve as exciting targets for cancer therapy. Current TAM receptor-directed therapies in preclinical development and clinical trials may have anti-cancer effects though impacting macrophage phenotype and function in addition to the cancer cells.
引用
收藏
相关论文
共 48 条
  • [1] Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment
    Myers, Kayla V.
    Amend, Sarah R.
    Pienta, Kenneth J.
    MOLECULAR CANCER, 2019, 18
  • [2] Dual targeting of TAM receptors Tyro3, Axl, and MerTK: Role in tumors and the tumor immune microenvironment
    Wang, Kai-Hung
    Ding, Dah-Ching
    TZU CHI MEDICAL JOURNAL, 2021, 33 (03): : 250 - 256
  • [3] Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation
    Zhou, Junsong
    Yang, Aizhen
    Wang, Yucan
    Chen, Fengwu
    Zhao, Zhenzhen
    Davra, Viralkumar
    Suzuki-Inoue, Katsue
    Ozaki, Yukio
    Birge, Raymond B.
    Lu, Qingxian
    Wu, Yi
    CELL COMMUNICATION AND SIGNALING, 2018, 16
  • [4] Tyro3, Axl, Mertk receptor-mediated efferocytosis and immune regulation in the tumor environment
    Zhou, Liwen
    Matsushima, Glenn K.
    SIGNAL TRANSDUCTION IN CANCER AND IMMUNITY, 2021, 361 : 165 - 210
  • [5] Requirement of Gamma-Carboxyglutamic Acid Modification and Phosphatidylserine Binding for the Activation of Tyro3, Axl, and Mertk Receptors by Growth Arrest-Specific 6
    Geng, Ke
    Kumar, Sushil
    Kimani, Stanley G.
    Kholodovych, Vladyslav
    Kasikara, Canan
    Mizuno, Kensaku
    Sandiford, Oleta
    Rameshwar, Pranela
    Kotenko, Sergei V.
    Birge, Raymond B.
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [6] Regulation of bone homeostasis by MERTK and TYRO3
    Engelmann, Janik
    Zarrer, Jennifer
    Gensch, Victoria
    Riecken, Kristoffer
    Berenbrok, Nikolaus
    The Vinh Luu
    Beitzen-Heineke, Antonia
    Vargas-Delgado, Maria Elena
    Pantel, Klaus
    Bokemeyer, Carsten
    Bhamidipati, Somasekhar
    Darwish, Ihab S.
    Masuda, Esteban
    Burstyn-Cohen, Tal
    Alberto, Emily J.
    Ghosh, Sourav
    Rothlin, Carla
    Hesse, Eric
    Taipaleenmaki, Hanna
    Ben-Batalla, Isabel
    Loges, Sonja
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [7] TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting
    Peeters, Marlies J. W.
    Rahbech, Anne
    Straten, Per Thor
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (02) : 237 - 244
  • [8] Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition
    Demirsoy, Seyma
    Tran, Ha
    Liu, Joseph
    Li, Yunzhan
    Yang, Shengyu
    Aregawi, Dawit
    Glantz, Michael J.
    Jacob, Naduparambil K.
    Walter, Vonn
    Schell, Todd D.
    Olmez, Inan
    CANCERS, 2024, 16 (12)
  • [9] Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma
    Dantas-Barbosa, Carmela
    Lesluyes, Tom
    Le Loarer, Francois
    Chibon, Frederic
    Treilleux, Isabelle
    Coindre, Jean-Michel
    Meeus, Pierre
    Brahmi, Mehdi
    Bally, Olivia
    Ray-Coquard, Isabelle
    Sunyach, Marie-Pierre
    Le Cesne, Axel
    Mir, Olivier
    Bonvalot, Sylvie
    Toulmonde, Maud
    Italiano, Antoine
    Saintigny, Pierre
    Jean-Denis, Myriam
    Ducimetiere, Francoise
    Ranchere, Dominique
    El Sayadi, Hiba
    Alberti, Laurent
    Blay, Jean-Yves
    BRITISH JOURNAL OF CANCER, 2017, 117 (12) : 1787 - 1797
  • [10] The TAM receptor Tyro3 is a positive regulator of myelination
    Akkermann, Rainer
    Binder, Michele D.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (14) : NP17 - NP18